Clinical trials: First Line Treatment
Cancer, Breast Cancer
Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours
Add-Aspirin aims to assess whether regular aspirin use after standard curative therapy can prevent recurrence and improve survival in individuals with non-metastatic common tumours.
- Conditions
- Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer
- Trial name
- NCT02804815
- Testing
- Aspirin 100mg, Aspirin 300mg
- Where
- 82 sites in Ireland, United Kingdom
- Volunteers
- 11,000 people
- Sponsor
- University College, London
Acute Lymphoblastic Leukemia, Adult
RWE of Pediatric-like Protocol for AYA Patients With Ph-negative ALL
This is a multicenter, observational real world clinical trial with prospective follow up that will evaluate the treatment outcome of adolescent and young patients with ph-negative acute lymphoblastic leukemia with first-line…
- Trial name
- NCT05127148
- Testing
- Evaluation of survival and toxicities in AYA Ph-negative ALL patients treating in first line depending on risk category.
- Where
- 2 sites in Argentina
- Volunteers
- 100 people
- Sponsor
- Grupo Argentino de Tratamiento de la Leucemia Aguda
Acromegaly
Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
Acromegaly is a chronic disease caused by excessive secretion of growth hormone (GH) and mainly due to benign tumour localized in the pituitary gland.
- Trial name
- PRIMARYS (NCT00690898)
- Testing
- Lanreotide autogel 120 mg
- Where
- 27 sites in Belgium, Czechia and 7 more
- Volunteers
- 108 people
- Sponsor
- Ipsen
Prostate Cancer
Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer
Prostate cancer is the most common non-cutaneous cancer in men. Patients with recurrent or metastatic prostate cancer are treated with androgen-deprivation therapy, often termed castration therapy.
- Trial name
- NCT01620593
- Testing
- Metformin
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Renal Cell Carcinoma
To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma
To assess how dose reductions or treatment interruptions related to axitinib can be implemented to manage and resolve adverse events occurring among patients with advanced renal cell carcinoma treated with first-line axitinib in…
- Trial name
- NCT04682587
- Testing
- Axitinib, Avelumab, Pembrolizumab
- Where
- United States
- Volunteers
- 481 people
- Sponsor
- Pfizer
Gastric Carcinoma
Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer
Cisplatin, an intravenously administered platinum agent, in combination with an intravenously administered taxane and capecitabine has been shown to improve time to disease progression and overall survival in previously untreated…
- Trial name
- NCT01348009
- Testing
- Tesetaxel-capecitabine-cisplatin
- Where
- South Korea
- Volunteers
- 63 people
- Sponsor
- Genta Incorporated
Metastatic Colorectal Cancer
FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type
BACKGROUND: For patients with liver-limited metastatic colorectal cancer (mCRC), complete resection of liver metastases is the only potentially curative treatment.
- Trial name
- FORBES (NCT02350530)
- Testing
- FOLFOXIRI + Bevacizumab, FOLFOXIRI
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Sun Yat-sen University
Malignant Melanoma
UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
This is a randomized, open label study to investigate efficacy and safety of UV1 vaccination in combination with nivolumab and ipilimumab as first line treatment of adult patients with histologically confirmed unresectable…
- Trial name
- NCT04382664
- Testing
- UV1, Sargramostim, Ipilimumab
- Where
- 37 sites in United States, Belgium and 2 more
- Volunteers
- 156 people
- Sponsor
- Ultimovacs ASA
Breast Cancer
Docetaxel, Capecitabine, and Bevacizumab in Treating Patients With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00088998
- Testing
- bevacizumab, capecitabine, docetaxel
- Volunteers
- 46 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma
A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma
To evaluate the efficacy and safety of TQB2618 injection combined with Penpulimab and chemotherapy in the first-line treatment of relapsed/metastatic head and neck squamous cell carcinoma compared to Penpulimab combined…
- Trial name
- NCT05783921
- Testing
- TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin, Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin
- Where
- 12 sites in China
- Volunteers
- 60 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Stomach Neoplasms
Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer
The goal of this clinical trial is to explore the efficacy and safety in patients with gastric adenocarcinoma or adenocarcinoma of esophagogastric junction.
- Trial name
- NCT05795296
- Testing
- Fruquintinib, Sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- RenJi Hospital
HSCT, Ph+ ALL
Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALL
To study the minimal residual disease (MRD) clearance rate of olverembatinib combined with inotuzumab ozogamicin as first-line consolidation chemotherapy in patients with Philadelphia chromosome-positive acute lymphoblastic…
- Trial name
- NCT07443488
- Testing
- Olverembatinib+INO
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Elderly Patients, Metastatic Colorectal Cancer
QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.
A national, multicenter, open-label, randomized phase III study. The trial aim is to determine the best therapeutic strategies according with the HRQoL.
- Conditions
- Elderly Patients, Metastatic Colorectal Cancer, Quality of Life
- Trial name
- COLAGE (NCT03828227)
- Testing
- OPTIMOX-bevacizumab, Capecitabine plus bevacizumab
- Where
- 22 sites in France
- Volunteers
- 49 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Unresectable Hepatocellular Carcinoma
Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC
This is a multicenter, randomized, open-label clinical study to evaluate the efficacy and safety of Adebrelimab plus Apatinib (cohort 1), or Adebrelimab plus Bevacizumab (cohort 2), or Camrelizumab plus Apatinib (cohort 3) as…
- Trial name
- NCT06360042
- Testing
- Adebrelimab plus Apatinib, Adebrelimab plus Bevacizumab, Camrelizumab plus Apatinib
- Where
- China
- Volunteers
- 111 people
- Sponsor
- Peking University Cancer Hospital & Institute
Chronic Myelogenous Leukemia
Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia
Our goal is to demonstrate that 50mg of dasatinib is as effective as the full dose to induce molecular response as first line therapy in CML.
- Trial name
- NCT03216070
- Testing
- Dasatinib 50 MG
- Where
- Mexico
- Volunteers
- 12 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Colorectal Cancer Metastatic
Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study
The main objective of this study is to evaluate the objective response rate at two months (complete disappearance of the disease and partial disappearance of the disease) obtained after administration of combination therapy with…
- Trial name
- REGAIN (NCT02316496)
- Testing
- cetuximab, Irinotecan
- Where
- 20 sites in France
- Volunteers
- 2 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Advanced Unresectable Hepatocellular Carcinoma
A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
This study was a multicenter, open-label phase I clinical trial. This trial will include 36 patients with advanced unresectable hepatocellular carcinoma.
- Trial name
- NCT07478302
- Testing
- SHR-2524 Injection, Bevacizumab Injection
- Where
- 2 sites in China
- Volunteers
- 36 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Urothelial Carcinoma, Urothelial Carcinoma Bladder
9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
This study will compare the efficacy of 9MW2821+toripalimab versus 9MW2821 monotherapy in locally advanced or metastatic urothelial carcinoma patients who have not received any systemic treatment in the metastatic or advanced…
- Conditions
- Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent, Urothelial Carcinoma of the Renal Pelvis and Ureter
- Trial name
- NCT06823427
- Testing
- 9MW2821, Toripalimab (JS001 )
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Lung Cancer Non-small Cell Stage IV
Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform
In order to understand the efficacy and side effects of lung cancer immunotherapy, at least 30 patients with lung cancer who were treated with immunotherapy were enrolled.
- Trial name
- NCT03692442
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Hypertension
Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension
The purpose of this clinical research is to learn if moderate hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P)…
- Trial name
- NCT00095550
- Testing
- Irbesartan/HCTZ, Irbesartan monotherapy, HCTZ monotherapy
- Where
- 128 sites in United States, Canada and 3 more
- Volunteers
- 496 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.